Title:
抗ＣＤ３３抗体及びその使用方法
Document Type and Number:
Japanese Patent JP7299160
Kind Code:
B2
Abstract:
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
More Like This:
Inventors:
Culp, Patricia
Lamb, Helen
Rosenthal, Arnon
Lee, Sunju
Neilson, Nels P.
Péjart, Robert
Lamb, Helen
Rosenthal, Arnon
Lee, Sunju
Neilson, Nels P.
Péjart, Robert
Application Number:
JP2019559021A
Publication Date:
June 27, 2023
Filing Date:
August 02, 2018
Export Citation:
Assignee:
Alexandr Elsie
International Classes:
C12N15/13; A61K39/395; A61P25/28; A61P35/00; A61P35/02; C07K16/28; C07K16/46; C12N1/15; C12N1/19; C12N1/21; C12N5/10; C12N15/62; C12N15/63; C12P21/08
Domestic Patent References:
| JP2015520758A | ||||
| JP2014500003A | ||||
| JP2006505277A |
Foreign References:
| WO2016201388A2 | ||||
| WO2016201389A2 | ||||
| WO2012074097A1 |
Other References:
MALIK, M. et al.,Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia,Human Molecular Genetics,2015年,Vol.24, No.12,p.3557-3570
PAREKH, B. S. et al.,Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay,MAbs,2012年,Vol.4, No.3,p.310-318
MIMOTO, F. et al.,Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131),Protein Engineering Design and Selection,2013年,Vol.26, No.10,p.589-598
LEOH, L. S. et al.,Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1,Molecular Immunology,2015年,Vol.67,p.407-415
YU, Y. J. et al.,Developing therapeutic antibodies for neurodegenerative disease,Neurotherapeutics,2013年,Vol.10,p.459-472
PAREKH, B. S. et al.,Development and validation of an antibody-dependent cell-mediated cytotoxicity-reporter gene assay,MAbs,2012年,Vol.4, No.3,p.310-318
MIMOTO, F. et al.,Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131),Protein Engineering Design and Selection,2013年,Vol.26, No.10,p.589-598
LEOH, L. S. et al.,Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1,Molecular Immunology,2015年,Vol.67,p.407-415
YU, Y. J. et al.,Developing therapeutic antibodies for neurodegenerative disease,Neurotherapeutics,2013年,Vol.10,p.459-472
Attorney, Agent or Firm:
Sonoda & Kobayashi Patent Attorneys Corporation
Previous Patent: Terminal, wireless communication method, base station and system
Next Patent: SOCCER BALL
Next Patent: SOCCER BALL